How to Read a Menopause Headline

You’ve seen them. You’ve probably screenshotted a few.

“Estrogen PROVEN to slash breast cancer risk.” “This one supplement ends hot flashes.” “Scientists discover the REAL cause of menopause belly.” They show up between a recipe and your cousin’s vacation photos, usually with an urgent font and someone pointing at floating text.

And if you’re like most of us, you feel two things at once. Hope, because maybe this is finally the answer. And a small sinking suspicion, because you’ve been let down before.

Keep that suspicion. It’s not cynicism. It’s a skill. And after decades of being dismissed by people who were supposed to know better, you’ve earned the right to check their work, and everybody else’s.

Here’s how.

Key takeaways:

–           Check who was studied. Before 1993, women were often underrepresented in the studies that set drug doses.

–           Conference presentations are early findings; peer-reviewed journal publication carries more weight.

–           Observational studies show associations, not cause; healthy-user bias can inflate apparent benefits.

–           Relative risk (“60% lower”) needs absolute numbers (out of 100 or 1,000) to be useful.

–           Menopause research is scarce (NIH: $56 million in 2023, about 0.12% of its budget), so early findings get over-stretched.

Why this matters more for us

Menopause research is thin. The NIH spent $56 million on it in 2023, barely one-tenth of one percent of its budget, and 2023 was the first year it even counted menopause as its own research category.

When real research is scarce, every new finding gets stretched to cover more ground than it can hold. A small study becomes “science says.” A conference poster becomes “proven.” And the women with the most urgent questions, us, get handed the stretchiest version.

That’s not your fault. That’s what happens in a gap. But it means the most useful thing we can hand you isn’t one more statistic. It’s the five questions that tell you how much weight a statistic can carry.

A real example: the headline that went viral

In October 2025, researchers presented findings at The Menopause Society’s annual meeting. They’d looked at more than 120 million electronic health records, and they found that women who started estrogen during perimenopause and used it for at least ten years had roughly 60% lower odds of breast cancer, stroke, and heart attack than women who started after menopause or never used it.

Within days, social media had turned that into “estrogen in perimenopause is proven to dramatically reduce breast cancer.”

Here’s what the lead investigator actually said: the results were “very preliminary,” and “we can’t draw the conclusion from our results that starting estrogen during perimenopause is safer.” The Menopause Society’s own medical director pointed to a well-known problem with this kind of study, called healthy-user bias, which we’ll get to.

Same data. Two completely different stories. Let’s walk through how to tell which one is true.

Question 1: Who was studied?

Before you ask what a study found, ask who it found it in.

Was it women? Women your age? Women in perimenopause, or women twenty years past menopause? Was it people at all, or mice, or cells in a dish?

This isn’t a small detail. For most of modern medicine, the default research subject was a man, the “70-kilogram reference man” medicine built its dosing models on. Before 1993, women were often underrepresented in the studies that set drug doses. That’s how a sleep drug approved in 1992 ended up needing its dose for women cut in half in 2013. Average blood levels were about 50% higher in women, and it had nothing to do with body size.

So when a headline says “study shows,” your first move is: shows it in whom? Mice aren’t menopausal women. Men aren’t menopausal women. Even women 70 and older may not tell you much about a 47-year-old in perimenopause.

Question 2: Published, or presented?

There’s a big difference between a study that has been peer-reviewed and published in a journal and one that was presented at a conference.

Conference presentations, often called abstracts or posters, are early looks. They’re valuable. Science needs them. But they haven’t yet gone through the full process where independent experts pick the methods apart before publication.

The 120-million-record estrogen finding was a conference presentation. That doesn’t make it wrong. It makes it early.

What to look for: a journal name in the source. If the only source is “presented at” a meeting, or a press release, or someone’s video, treat it as a first draft of the truth, not the final version.

Question 3: “Linked to,” or “causes”?

This one is the whole ballgame.

Most headlines you’ll see come from observational studies. Researchers look at what people already did and what happened to them. They’re incredibly useful for spotting patterns. But they can’t, by themselves, prove that one thing caused another.

Here’s the classic trap, and it applies directly to the estrogen example. Women who start hormone therapy early and stay on it for a decade may differ from other women in lots of ways. They may have better access to care, more checkups, more money, and healthier habits. Researchers call this healthy-user bias: people who take a treatment consistently are often healthier to begin with. So the lower risk might come partly from the treatment and partly from who takes it.

The tell: watch the verbs. “Linked to,” “associated with,” and “tied to” are honest about what an observational study can show. “Prevents,” “causes,” “slashes,” and “proven” usually mean somebody upgraded the finding somewhere between the lab and your feed.

A randomized controlled trial, where people are assigned to a treatment or a comparison by chance, can get much closer to cause and effect. Those are rarer, slower, and more expensive, which, given the funding numbers above, is exactly why we don’t have more of them.

Question 4: How big, compared to what?

“60% lower!” sounds enormous. But 60% lower than what?

Headlines almost always report relative risk, the percent change. What you actually need is absolute risk: how many women out of 100, or out of 1,000, it actually affects.

If something drops a risk from 2 in 1,000 to 1 in 1,000, that’s a 50% relative reduction. It’s also one woman in a thousand. Both numbers are true. Only one helps you make a decision.

The question to ask your provider: “Out of 100 women like me, how many would this actually help, and how many would it harm?” A good clinician can answer that, or will look it up with you. It’s one of the most useful sentences you can take into an exam room.

Question 5: Who paid, and who’s selling?

Follow the money. Not because industry-funded research is automatically wrong (much of medicine depends on it), but because you deserve to know.

We hold ourselves to this. When we cite a survey commissioned by a company that sells hormone therapy, we say so every time. When we cite a large survey done through a period-tracking app, we note that the women who answered were already tracking their health, which may not represent everyone.

Ask the same of every headline: Who funded this? Is the person sharing it selling something? A supplement brand promoting “a study” on its own supplement is a very different thing from an independent trial published in a major journal.

The five questions, in one place

Save this. Screenshot it. Send it to your group chat.

1.          Who was studied? Women? My age? My stage? Humans?

2.          Published or presented? A peer-reviewed journal, a conference, a press release, or a video?

3.          Linked to, or causes? Observational, or a randomized trial?

4.          How big, compared to what? Relative risk, or actual numbers out of 100?

5.          Who paid, and who’s selling?

You don’t need a medical degree to ask these. You need the confidence to ask them out loud, and you have every right to it.

What this doesn’t mean

It doesn’t mean ignoring new research. Some of the most important progress in menopause care started as an early finding someone took seriously enough to test properly.

It doesn’t mean distrusting your provider. The goal isn’t to argue. It’s to walk in as a partner who asks good questions.

And it definitely doesn’t mean you were foolish for hoping. Hope is what got you reading in the first place.

The point: a headline is where a conversation starts, not where it ends.

You were never “bad at science”

For generations, women were told this stuff was too complicated for us. Leave it to the experts. Don’t worry your “pretty head.”

Meanwhile, some of those same experts left women out of the studies.

You’re not bad at science. You were shut out of it. Every time you ask “who was studied?” or “compared to what?”, you’re doing exactly what good scientists do, and you’re making it a little harder for anyone to sell you a half-truth again.

That’s not a small thing. That’s how a movement reads the fine print.

— Delaney


Want the receipts, with the sources, for everything in the menopause conversation? That’s the whole point of You’re Not Crazy... You’re Menopausal: Science, Strategies, and Swearing Through the Hormonal Apocalypse, at notcrazymovement.com/book. And get the free 7-Day Symptom Tracker + Doctor Visit Guide at notcrazymovement.com. It includes the questions to bring to your next appointment.

Medical note: This article is educational and is not medical advice. Talk to your healthcare provider about how any research applies to you.



Sources & References

1.          Healio. “Initiating estrogen therapy during perimenopause may protect against cancer, stroke.” October 21, 2025, reporting an abstract presented at The Menopause Society 2025 Annual Meeting. healio.com

2.          The 19th. “What influencers got wrong about a new study on estrogen and perimenopause.” October 2025. 19thnews.org

3.          U.S. Food and Drug Administration. Drug Safety Communication: zolpidem dosing for women. January 10, 2013.

4.          NIH Revitalization Act of 1993 (inclusion of women in clinical research).

5.          National Institutes of Health. RCDC categorical spending, menopause category, 2023. report.nih.gov

6.          Biote survey, November 2025 (industry-commissioned, self-selected), and Flo app survey, Menopause, 2026 (self-selected), cited as disclosure examples.

Delaney Cassidy

Delaney Cassidy is a seasoned healthcare professional and the founder of the Not Crazy Movement. She started by asking why she felt like she was losing her mind—and why every doctor looked at her like she was overreacting. She wasn’t. She was navigating perimenopause, and the answers were buried under decades of research that never really included women. Now she hands them back: the science, the receipts, and the permission to be angry about the gap. She’s the author of You’re Not Crazy... You’re Menopausal: Science, Strategies, and Swearing Through the Hormonal Apocalypse. Recognition. Research. Respect.

https://notcrazymovement.com
Next
Next

One Year Later: The Shortage That Proved the Demand